1350925-22-2

Basic information

• Product Name: 3,6-dichloropyrido[2,3-b]pyrazine
• Synonyms: 3,6-dichloropyrido[2,3-b]pyrazine
• CAS NO: 1350925-22-2
• Molecular Formula: C7H3Cl2N3
• Molecular Weight: 200.02482
• Mol File: 1350925-22-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,6-dichloropyrido[2,3-b]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-dichloropyrido[2,3-b]pyrazine(1350925-22-2)
• EPA Substance Registry System: 3,6-dichloropyrido[2,3-b]pyrazine(1350925-22-2)

Safety Data

• Hazardous Substances Data: 1350925-22-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,6-dichloropyrido[2,3-b]pyrazine serves as a key building block in the development of various pharmaceuticals. Its incorporation into drug molecules enhances their therapeutic potential, making it an essential component in the synthesis of a range of medications.
Used in Agrochemical Industry:
In the agrochemical sector, 3,6-dichloropyrido[2,3-b]pyrazine is employed as an intermediate in the production of pesticides. Its unique structure contributes to the effectiveness of these chemicals in controlling pests and diseases, thereby playing a crucial role in ensuring agricultural productivity.

Upstream product

• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 1350925-21-1 6-chloropyrido[2,3-b]pyrazin-3(4H)-one 
• 1350925-20-0 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one 
• 1350925-19-7 ethyl 2-(2-amino-6-chloropyridin-3-ylamino)acetate 
• 146015-42-1 6-chloro-2-nitropyridine-3-amine 
• 40851-95-4 6-chloropyridine-2,3-diamine 

Downstream Products

• 1431873-09-4 C₄₀H₃₄N₁₀O₂ 
• 1431873-08-3 C₄₁H₃₅N₉O₂ 
• 1431873-07-2 C₁₈H₁₄Cl₂N₆O 
• 1431873-06-1 C₁₉H₁₆F₂N₆O₂ 
• 1431872-83-1 C₂₆H₂₈FN₇O₄ 
• 1431873-04-9 C₂₇H₃₆N₆O₃Si 
• 1431872-56-8 C₂₈H₂₅N₇O₃ 
• 1431873-03-8 C₁₉H₁₇FN₆O₂ 
• 1431872-17-1 C₂₅H₂₅FN₁₀O₂ 
• 1431872-12-6 C₂₃H₂₀FN₉O 
• 1431872-08-0 C₂₁H₂₀FN₇O₃ 
• 1431873-02-7 C₂₀H₂₀N₆O₂ 
• 1431871-88-3 C₂₁H₁₇F₂N₇O₂ 
• 1431871-85-0 C₂₄H₂₅FN₆O₃ 

Relevant articles and documents

A 2,7-diamino-1,4,8-triazanaphthalene derivative selectively binds to cytosine bulge DNA only at a weakly acidic pH

The synthesis and properties of 2,7-diamino-1,4,8-triazanaphthalene (azaDANP) are described. AzaDANP is protonated only at a weakly acidic pH to bind to the cytosine bulge DNA duplex selectively. Upon binding of azaDANP to the cytosine bulge DNA, a new absorption band at 407 nm appears, and the absorption change of azaDANP on binding to the target is very sensitive to environmental pH with a bell-shaped pH-absorption profile.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.